NCT03568968 (NOPARK) is a Phase 3 clinical trial of Nicotinamide Riboside in Parkinson Disease, sponsored by Haukeland University Hospital.

Who is sponsoring NCT03568968?

NCT03568968 is sponsored by Haukeland University Hospital.

What drugs are being tested in NCT03568968?

Interventions in NCT03568968: Nicotinamide Riboside, Placebo.

What condition does NCT03568968 study?

NCT03568968 studies Parkinson Disease.

Is NCT03568968 still recruiting?

NCT03568968 is currently completed. Last updated 26 September 2025.

Last reviewed 2025-09-26 · How we verify

NCT03568968: NOPARK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease

Completed Phase 3 Last updated 26 September 2025

What this trial tests

Phase 3 trial testing Nicotinamide Riboside in Parkinson Disease in 410 participants. Completed in 17 June 2025.

Timeline

6 May 2020

Primary endpoint
17 June 2025

17 June 2025

Quick facts

Lead sponsor	Haukeland University Hospital
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	410
Start date	6 May 2020
Primary completion	17 June 2025
Estimated completion	17 June 2025
Sites	11 locations across Norway

Drugs / interventions tested

Nicotinamide Riboside — full drug profile →
Placebo

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Haukeland University Hospital

Who can join

35 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

NOPARK is a double-blinded randomized controlled phase II trial, with the aim to assess the efficacy of nicotinamide adenine dinucleotide (NAD)-replenishment therapy in the form of oral nicotinamide riboside (NR) in delaying the progression of early Parkinson's disease (PD). A total of 400 persons with early stage Parkinson's disease will be enrolled, randomized on nicotinamide riboside (NR) 500mg x 2 per day or placebo, and followed for 52 weeks.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Epigenetic regulation of aging: implications for interventions of aging and diseases.
Wang K, Liu H, Hu Q, Wang L, et al · · 2022 · cited 406× · PMID 36336680 · DOI 10.1038/s41392-022-01211-8
The Genetics of Parkinson's Disease and Implications for Clinical Practice.
Day JO, Mullin S. · · 2021 · cited 159× · PMID 34208795 · DOI 10.3390/genes12071006
Targeting mitophagy in Parkinson's disease.
Clark EH, Vázquez de la Torre A, Hoshikawa T, Briston T. · · 2021 · cited 94× · PMID 33372898 · DOI 10.1074/jbc.rev120.014294
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update.
McFarthing K, Buff S, Rafaloff G, Fiske B, et al · · 2023 · cited 72× · PMID 37302040 · DOI 10.3233/jpd-239901
Mitophagy and the Brain.
Swerdlow NS, Wilkins HM. · · 2020 · cited 51× · PMID 33352896 · DOI 10.3390/ijms21249661
Clinical Evidence for Targeting NAD Therapeutically.
Radenkovic D, Reason, Verdin E. · · 2020 · cited 45× · PMID 32942582 · DOI 10.3390/ph13090247
Base excision repair causes age-dependent accumulation of single-stranded DNA breaks that contribute to Parkinson disease pathology.
SenGupta T, Palikaras K, Esbensen YQ, Konstantinidis G, et al · · 2021 · cited 44× · PMID 34496255 · DOI 10.1016/j.celrep.2021.109668
The Promise of Niacin in Neurology.
Wuerch E, Urgoiti GR, Yong VW. · · 2023 · cited 38× · PMID 37084148 · DOI 10.1007/s13311-023-01376-2

Verify or expand the search:

Other trials of Nicotinamide Riboside

Trials testing the same drug.

NCT06587945 — Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment · Phase 4 · recruiting
NCT06991712 — Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients · Phase 2 · recruiting
NCT07073352 — ACEs, SIRT1, and Premature Vascular Aging in Humans · NA · recruiting
NCT06032923 — Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabo · Phase 1, PHASE2 · recruiting
NCT06044935 — Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate · NA · recruiting

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Haukeland University Hospital trials

Trials by the same sponsor.

NCT07450105 — Intensive Dialectical Behavior Therapy for Self-Harm and Suicidal Behavior in Youth: A Pilot Study · NA · not yet recruiting
NCT07450092 — Prehospital Use of Forced Air Warming · NA · enrolling by invitation
NCT07268716 — Assess the Efficacy of Tailored Patient Information and Voluntary Patient-managed Outpatient Digital Follow-up (I-POD) a · NA · not yet recruiting
NCT07392697 — The Intravenous Amino Acid Therapy for Vascular Rigidity in End Stage Renal Disease · NA · not yet recruiting
NCT07304219 — Physical Activity Based Treatment for Youth With Depression and Anxiety · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03568968 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Haukeland University Hospital
Last refreshed: 26 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03568968.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing